3rd Molecular Glue Drug Development Summit

Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion. The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.

Event Links

Website: https://go.evvnt.com/2697860-0

Tickets: https://go.evvnt.com/2697860-2

Brochure: https://go.evvnt.com/2697860-3

Read More

View Less